Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data

Siegel, 2020, Cancer statistics, 2020, CA Cancer J. Clin., 70, 7, 10.3322/caac.21590 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Gonzalez Bosquet, 2016, Prediction of chemo-response in serous ovarian cancer, Mol. Cancer, 15, 10.1186/s12943-016-0548-9 Damia, 2019, Platinum resistance in ovarian cancer: role of DNA repair, Cancers (Basel), 11, 10.3390/cancers11010119 van Zyl, 2018, Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment, Endocr. Relat. Cancer, 25, R303, 10.1530/ERC-17-0336 Eckstein, 2011, Platinum resistance in breast and ovarian cancer cell lines, J. Exp. Clin. Cancer Res., 30, 10.1186/1756-9966-30-91 Hartmann, 2005, Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy, Clin. Cancer Res., 11, 2149, 10.1158/1078-0432.CCR-04-1673 Yu, 2016, Predicting ovarian cancer patients’ clinical response to platinum-based chemotherapy by their tumor proteomic signatures, J. Proteome Res., 15, 2455, 10.1021/acs.jproteome.5b01129 Luo, 2016, Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer, Medicine (Baltimore), 95, 10.1097/MD.0000000000004797 Rauh-Hain, 2013, Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma, Gynecol. Oncol., 129, 63, 10.1016/j.ygyno.2013.01.009 Timmermans, 2019, Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer, Eur. J. Obstet. Gynecol. Reprod. Biol., 240, 364, 10.1016/j.ejogrb.2019.07.010 Steyerberg, 2014, Towards better clinical prediction models: seven steps for development and an ABCD for validation, Eur. Heart J., 35, 1925, 10.1093/eurheartj/ehu207 Davis, 2014, “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?, Gynecol. Oncol., 133, 624, 10.1016/j.ygyno.2014.02.038 Mackay, 2010, Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer, Int. J. Gynecol. Cancer, 20, 945, 10.1111/IGC.0b013e3181dd0110 da Costa, 2015, Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer, Ann. Surg. Oncol., 22, S971, 10.1245/s10434-015-4623-z Petrillo, 2013, Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy, Ann. Surg. Oncol., 20, 3955, 10.1245/s10434-013-3091-6 Timmermans, 2018, Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands, Eur. J. Obstet. Gynecol. Reprod. Biol., 223, 98, 10.1016/j.ejogrb.2018.02.029 Madariaga, 2019, Tailoring ovarian cancer treatment: implications of BRCA1/2 mutations, Cancers (Basel), 11, 10.3390/cancers11030416 Yang, 2011, Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer, JAMA, 306, 1557, 10.1001/jama.2011.1456 Gadducci, 2019, Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status, J. Ovarian Res., 12, 10.1186/s13048-019-0484-6 Vos, 2019, Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition, J. Natl. Cancer Inst. Arts-de Jong, 2016, Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review, Eur. J. Cancer, 61, 137, 10.1016/j.ejca.2016.03.009 Zeng, 2017, The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery, J. Cancer, 8, 3410, 10.7150/jca.21362